SLATE-001 is under clinical development by Gritstone Bio and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SLATE-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SLATE-001 overview
SLATE-001 is under development for the treatment of KRAS mutant metastatic solid cancer including gastrointestinal, genitourinary, breast, ovarian, non-small cell lung cancer (NSCLC) and other solid cancers, pancreatic ductal adenocarcinoma, metastatic colorectal cancer and solid tumors. It is administered through intramuscular and parenteral route. It is a personalized tumor specific neoantigen candidate, comprises of fixed cassette of a chimpanzee adenovirus vector (ChAdV) and self-amplifying mRNA (SMA) boost. It is developed based on lipid nanoparticle (LNP) technology. It is developed based on EDGE antigen discovery platform.
See Also:
Gritstone Bio overview
Gritstone Bio (Gritstone), formerly Gritstone Oncology, is a clinical-stage biotechnology company. The company discovers, develops, manufactures, and delivers vaccine-based immunotherapy candidates against cancer and infectious diseases. It develops personalized cancer vaccines designed to direct a robust immune response to neoantigens by leveraging its artificial intelligence Gritstone EDGE platform. Gritstone’s cancer vaccines product pipeline includes GRANITE and SLATE for solid tumors; and prophylactic samRNA (CORAL), HIV Therapeutic vaccine, and other flu, multi-respiratory, papillomavirus (HPV) eradication pathogens. The company designs immunotherapy containing the relevant neoantigens to be administered by intramuscular injection. It manufactures products through its biomanufacturing facilities in Massachusetts, and California, the US. Gritstone is headquartered in Emeryville, California, the US.
For a complete picture of SLATE-001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
